SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Elon Musks warning that tighter debt markets could trigger failures and consolidation among AI neoclouds has fueled concern about Nebiuss capital-intensive expansion and weighed on sentiment. Bulls counter that Nebius has secured financing and customer commitments, arguing it is better positioned than weaker sector peers; others remain concerned about debt access and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

Elon Musks warning that many neocloud operators could fail or consolidate, alongside concerns about debt-heavy AI data-center expansion and tighter financing, is driving attention to IREN and its peers. Traders debate whether the comments amplify genuine funding and execution risks or are self-interested criticism, with bulls pointing to IRENs contracts and infrastructure while bears warn of further losses.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas positive Phase 3 melanoma-vaccine results with Mercks Keytruda have driven discussion, but shares sold off as traders judged the data against heightened expectations and questioned the treatments commercial potential. Bulls view the results as validation for a broader cancer-vaccine platform, while skeptics point to approval, adoption and profitability uncertainties and await evidence in other cancers.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils presidential election has driven sharp swings in Brazilian stocks, including NU, as traders react to political and economic uncertainty. The community is split between viewing the selloff as a buying opportunity and waiting for the stock to stabilize, with some arguing the companys fundamentals remain strong.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs event-driven Phase 3 REGAL trial of its GPS leukemia vaccine dominates discussion, with traders focused on the final analysis triggered at 80 survival events and anticipating a possible data update around ASH. Bulls speculate the prolonged wait could reflect a survival benefit, while skeptics question the delay, the companys quiet period, and whether the blinded trial will ultimately succeed; SLS009 updates are a secondary catalyst.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory after markets had positioned for a Bolsonaro win prompted a sharp selloff in Brazilian shares, including Petrobras. Traders are divided between concerns about political and dividend risks under Lula and the view that the decline is an overreaction given Petrobras oil business and valuation.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

EWZ is drawing attention after Brazils unexpected Lula victory triggered a sharp selloff, as traders worry about political and economic uncertainty and the markets apparent positioning for a Bolsonaro win. Many are bearish on Brazils outlook, while others argue the decline is an overreaction and see a potential buying opportunity.

XP, Inc. engages in the operation of technology-driven financial services platform. The firm provides customers with two principal types of offerings, financial advisory services for retail clients in Brazil, high-net-worth clients, international clients and corporate and institutional clients, and an open financial product platform providing access to over 800 investment products including equity and fixed income securities, mutual and hedge funds, structured products, life insurance, pension plans, real-estate investment funds (REITs) and others from XP, its partners and competitors. he company was founded by Guilherme Dias Fernandes Benchimol in 2001 and is headquartered in Vila Olimpia, Brazil.

XP Inc - Ordinary Shares - Class A

XP Inc. is trending as investors react to a new capital optimization plan, which includes a significant buyback program and planned dividend distributions, while the community remains divided over the firm's long-term growth prospects and the broader volatility of Brazilian financial stocks. Discussion is heavily focused on whether these capital return initiatives can stabilize the share price following a multi-year downtrend and ongoing skepticism regarding the company's reliance on specific high-volatility financial products.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCelleras ABCL635 clinical results for menopausal hot flashesand its presentation of additional Phase 1/2 safety and patient-reported dataare the dominant focus, alongside anticipation for further durability data. The reaction is largely bullish on the program and its potential, while some traders caution that expectations may be high and the stock could consolidate or sell off without stronger new evidence.

iShares Trust - iShares Biotechnology ETF

iShares Biotechnology ETF

Biotech is pulling back after a recent sector rally, with traders debating whether the weakness is a pause or a broader deterioration. IBBs hold near its 50-day moving average is cited as support, while some see large-cap biotech holding up better than smaller names.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar?

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

IMAX Stock Slides After-Hours As CEO Goes On Temporary Leave Of Absence 

Equity

Consistent with IMAX’s operating plan in the event of its CEO Richard Gelfond’s temporary absence, the firm’s senior executives are executing their day-to-day responsibilities. 


Janus Detroit Street Trust - Janus Henderson Small/Mid Cap Growth Alpha ETF

Neutral Sentiment

<ul class="summary-bullets"><li>While Gelfond receives medical care and recovers, he will not be participating in any public or private events for the company, the statement said.&nbsp;</li><li>IMAX is a leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems.</li><li>Earlier in the month, Goldman Sachs raised the firm's price target on Imax to $41 from $37 and kept a ‘Neutral’ rating on the shares.&nbsp;</li></ul><p>Imax Corp. (IMAX)&nbsp;on Monday announced that CEO Richard Gelfond&nbsp;would be&nbsp;on a temporary medical leave of absence as he undergoes treatment for pneumonia.</p><p>Shares in the company fell 2% during extended hours of trading.&nbsp;</p><p>While Gelfond receives medical care and recovers, he will not be participating in any public or private events for the company, the&nbsp;company said.&nbsp;</p><p>Consistent with its operating plan in the event of Gelfond’s temporary absence, the firm’s senior executives are executing their day-to-day responsibilities in coordination with each other and Board Chairman Darren Throop, with regular communication with the full board of directors.&nbsp;</p><p>“We have a strong, deeply experienced senior executive team who are fully engaged, providing regular updates to the Board, and remain focused as always on the continued growth and success of IMAX. We are all wishing Rich well and a full and speedy recovery,” Throop said.&nbsp;</p><h2 class="st-heading-2">About IMAX</h2><p>IMAX is a leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems.</p><p>Headquartered in New York, Toronto, and Los Angeles, IMAX operates 1,864 systems across 91 countries and territories as of December 31, 2025.</p><h2 class="st-heading-2">Recent Analyst Actions</h2><p>Earlier in the month, Goldman Sachs raised the firm's price target on Imax to $41 from $37 and kept a ‘Neutral’ rating on the shares.&nbsp;</p><p>Late in February, B. Riley analyst Drew Crum raised the firm's price target on Imax to $46 from $44 and kept a ‘Buy’ rating on the shares.&nbsp;</p><p>JPMorgan raised the firm's price target on Imax to $48 from $47 and kept an ‘Overweight’ rating on the shares. The company reported another quarter with revenue and margin ahead of consensus, the analyst had told investors in a research note.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>Retail sentiment around IMAX stock trended in ‘bearish’ amid ‘normal’ message volume.&nbsp;</p><p>Shares in the company have risen almost 2% so far in 2026.&nbsp;</p>

In this photo illustration the IMAX logo is seen displayed on a smartphone. 

Consistent with IMAX’s operating plan in the event of its CEO Richard Gelfond’s temporary absence, the firm’s senior executives are executing their day-to-day responsibilities. 

American Century ETF Trust - Avantis U.S. Small Cap Value ETF

Imax Corp

iShares Russell 2000 Growth ETF

Janus Capital Management LLC - Janus Henderson Small/Mid Cap Growth Alpha ETF

Principal Exchange-Traded Funds - Principal U.S. Small-Cap Multi-Factor ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

JSMD Janus Capital Management LLC - Janus Henderson Small/Mid Cap Growth Alpha ETF

Fundamentals

Latest JSMD News